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Abstract 
 
For hospitals providing services to regional populations, difficulties are associated with 
transferred patients with poorly communicated medical history and a risk of 
alloimmunisation. Identification of patients at risk would assist in planning.    
A retrospective study of alloimmunised patients was undertaken, comparing the 
demographics and diagnoses of this population with a control patient population.  
A preponderance of diagnoses of Sepsis, Haematological Malignancy, GIT Bleeds and Renal 
Failure was demonstrated in the alloimmunised population. Consistant with prior studies, 
RhD negative patients and female patients were over-represented in the study group, which 
was also on average significantly older . 
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1. Introduction  
 
Our institution is a tertiary referral hospital and major trauma centre and regularly treats 
patients referred from other hospitals and regions, as well as traumas from a wide catchment 
area. These patients may have been treated in other institutions, including receiving 
allogeneic blood transfusions, and are therefore potentially at risk of previous 
alloimmunisation.  
 
A challenging aspect of these patients is that they may arrive with minimal medical history 
available, and the history of prior blood exposure is often unclear. Preoperative transfusion 
serology testing is regularly performed, often on the morning of the surgery, leaving little 
time to source antigen negative blood if alloantibodies are found. Both the trauma and 
preoperative scenario present situations where discovering that the patient has an 
alloantibody at the time of treatment can be particularly problematic.  
 
Due to the nature of the patient population it was considered advantageous to be able to 
‘profile’ the patient who was at high risk of having already been alloimmunised following red 
cell exposure. This would then provide an advanced warning of potentially high risk patients 
and, where possible, enable us to perform their transfusion serology testing earlier in order to 
allow for the detection and identification of these antibodies and the provision of suitable 
blood products.   
 
2. Materials and Methods 
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2.1 Patient Database  
A retrospective study was undertaken on patients in whom red cell alloantibodies were 
detected serologically by ACT Pathology Transfusion Laboratories from 2008 to 2011. A 
patient control group consisting of the total patients tested by the ACT Pathology Transfusion 
Laboratories in 2008 was used. Patient records were extracted from the Kestral Laboratory 
Information System using an existing data extraction for red cell antibodies, and additional 
information including the blood group and diagnosis was retrieved on a patient by patient 
basis. Diagnoses were drawn from the clinical notes supplied to ACT Pathology.  
 
Patients with proven prophylactic Anti-D were removed from the database, as were those 
with auto-antibodies and those whose antibodies had no definable specificity or were proven 
on further investigation to be cross-reacting white cell antibodies. The data was then de-
identified, with only the patient’s sex and year of birth being retained. This yielded a database 
of 589 alloimmunised patients and 12246 control patients. 
 
2.2 Statistical analysis 
Multivariate analyses for gender, ABO Blood Group, RhD status and diagnosis were 
performed using the Pearson’s Chi-square test. The mean and standard deviation of the age 
distribution of both patient groups were analysed using the Unpaired T Test. All analyses 
were calculated using GraphPad InStat software. P of less than or equal to 0.05 was 
considered statistically significant. 
 
3. Results 
 
The initial data extraction yielded 589 patients who presented to the ACT Pathology 
Transfusion Laboratories with red cell alloantibodies between 2008 and 2011. These patients’ 
full transfusion histories were further examined and 362 patients (61.4%) proved to have had 
antibodies detected on their initial presentation to the laboratories (which may have predated 
the investigative time frame) and thus had been transfused elsewhere.  
 
Of the 227 (38.6%) patients who initially presented without antibodies and were found on a 
later date to have become alloimmunised, 15 had neither a history of transfusion nor 
pregnancy as per ACT Pathology records. These patients had a mean of 5.28 years between 
their last negative antibody screen and their first positive one, indicating that they were likely 
to have received treatment elsewhere in the intervening years. It is the lack of this 
comprehensive treatment record that makes treating these patients particularly challenging.  
 
[Table 1] 
 
[Table 2] 
 
The patient and control databases were analysed for the ratios of male to female patients, 
ABO blood group and RhD status (Table 1). Analysis of the diagnoses of patients within both 
groups revealed an array of presentations, which have been broadly categorised (Table 2).  
 
There was a significantly higher proportion of females (P<0.001) in the alloimmunised 
population than in the control population. The alloimmunised patients were also significantly 
older, there being a difference between the means of 8.41yrs (P<0.001). 
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ABO status did not vary significantly between the alloimmunised patients and the control 
patients (P=0.54) however there was a significantly higher proportion of RhD Negative 
individuals in the alloimmunised group (P<0.001).  
 
The array of diagnoses were significantly different between the alloimmunised and control 
populations. The diagnoses of GIT Bleed, Haematological Malignancy, Renal Failure and 
Sepsis were all significantly higher in the alloimmunised population. Pregnancy was 
significantly under-represented in our alloimmunised population, an unexpected result. 
Diagnoses given but not otherwise listed were categorised as Other and were significantly 
lower, with only 21 patients in the alloimmunised group falling into that category. Other 
diagnostic categories did not show significantly different proportions within the populations.  
 
[Figure 1] 
 
[Figure 2] 
 
There was a distinct difference in age distribution between male and female patients in both 
the control and alloimmunised populations. Both groups show a peak amongst female 
patients of child-bearing age (Fig.2) which is clearly not present in male patients of similar 
ages (Fig.1), accounted for by the hospital’s function as an obstetric centre. Importantly for 
this study, both groups show a peak around the 70-90 years range.  
 
The entire tested population was extracted for 2008 as a control, the alloimmunised 
population for 2008-2011. Total patient numbers through the laboratory for the period 2008-
2011 were 58480. Based upon the data analysed, this gives an overall alloimmunsation rate 
amongst tested patients of 1.0%.  
 
4. Discussion 
 
The alloimmunised patient presents an added level of complexity in the transfusion situation, 
the unexpected alloimmunised patient even more so. Antigen negative red cells are required 
and, depending on the specificity of the antibody or antibodies present, matched blood may 
be difficult to source. Donor red cells must then be cross-matched using an Indirect 
Antiglobulin Technique which can further slow down the process, hindering access to what 
blood is available. Thus, greater preparation time for the provision of blood products should 
be allowed for patients with known red cell antibodies prior to events that may require 
transfusion. 
 
Amongst the 589 alloimmunised patients in this study, the diagnoses of GIT Bleed, 
Haematological Malignancy, Renal Failure and Sepsis were over-represented when compared 
with the control group. The first three diagnoses are directly associated with high levels of 
red blood cell transfusion. Sepsis is an acute diagnosis and not directly associated with red 
cell usage however it is more common following complex surgery or trauma, which are in 
turn situations which often involve high levels of blood use. A search of the literature did not 
reveal any other studies linking Sepsis with alloimmunisation.  
 
Alloimmunisation results primarily from exposure to immunogenic red cells through either 
transfusion or pregnancy, [1] and the greater the exposure, the greater the risk of the patient 
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having an immune response [2]. Therefore it is reasonable to deduce from the data that the 
higher usage of donor red cells in these diagnoses is directly linked to the higher rate of red 
cell antibody production. This compares with the findings of Koelewijn et al [3] whose study 
of pregnant women found that previous pregnancy, surgery and history of transfusion were 
significant risk factors for alloimmunisation. Steigler et al [4] also reported a high rate of 
alloimmunisation amongst patients with MDS and Renal failure.  
 
Female patients were found to be significantly over-represented in the alloimmunised 
population. If we assume a previous history of pregnancy amongst a proportion of female 
patients and therefore a corresponding rate of foetal red cell exposure, we can explain the 
higher rate of alloimmunised females amongst the patients studied. Whilst the introduction of 
Anti-D prophylaxis has reduced the rate of RhD alloimmunisations, it does not prevent it 
entirely, nor prevent the production of other antibodies during pregnancy [5]. Interestingly, 
Verduin et all [6] report a greater long-term persistence of foetal-induced red cell antibodies 
compared to transfusion induced alloimmunisation.  
 
Issitt and Anstee [7] estimated that the rate of presentation with a clinically significant red 
cell antibody was approximately 1% to 1.5% amongst patients and 0.2% amongst healthy 
blood donors. This is comparable with this study’s estimated overall alloimmunisation rate of 
1.2% for the period of 2008-2011. This is the rate across all patients encountered by the 
transfusion service. It is interesting to note that a large study in Hungary [8] found an 
alloimmunisation rate of 6.16% in the general patient population when the screening method 
included an enzyme technique to enhance detection of weak alloantibodies with enzyme-
enhanced specificities. The value of the detection of enzyme-only antibodies has been hotly 
debated in the literature, as the clinical significance of ‘enzyme only’ antibodies is dubious. 
 
The rate of red blood cell alloimmunisation varies greatly between studies and can be as high 
as 60% in patients transfused on a chronic basis [9]. Other studies report more modest rates; 
8.4% following transfusion during elective surgery [10], 6.1% amongst transfused patients in 
Uganda [11] and 7.9% amongst patients awaiting a liver transplant in the UK [12]. A study of 
chronically transfused thalassaemic patients found an alloimmunisation rate of 11.8%.[13] 
Given the nature of the study cohort and the initial problem of incomplete medical and 
transfusion histories across multiple sites, it was not possible to accurately assess each 
patient’s total blood unit exposure. This would have been interesting data to compare with the 
alloimmunisation rates but if available would render the study unnecessary.  
 
Whilst the patients’ ABO blood group did not differ significantly, the RhD status of the 
patient was found to be important in determining the likelihood of previous 
alloimmunisation, with RhD negative individuals significantly more likely to have red cell 
antibodies. RhD is recognised as the most immunogenic and clinically important red cell 
antigen after the ABO antigens, and is why it is routinely included in blood group testing 
[14].  
 
It was estimated by Klein and Anstee [1] that 85% of RhD negative individuals will produce 
an anti-D following transfusion with 200mLs of RhD positive blood. However a study by 
Yazer and Triulzi [15] found that of 98 RhD negative patients transfused with RhD positive 
blood, only 22 (22%) produced anti-D antibodies. Cerdas-Quesada [16] reported that 75% of 
antibodies produced by their study cohort were Rh antibodies.  It is interesting to note that 
Yazer and Triulzi [15] report that within their sub-cohort that received only leukodepleted red 
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blood cells, the RhD alloimmunisation rate dropped to 13%. Their lower reported rate of 
overall alloimmunisation may be due to increasing rates of leukodepletion and other 
improvements in packed red cell manufacturing. Following the introduction of Anti-D 
prophylaxis, the rate of RhD alloimmunisation in pregnancy is dropping, whilst the relative 
frequency of non-rhesus antibodies is rising [17]. 
 
The aging patient population requires a greater number of surgical procedures [18] and thus 
the older the patient the greater the probability that they have had a pregnancy or procedure 
that involved blood transfusion and thus exposure to red cell antigens. This is reflected in this 
study where the alloimmunised population shows a mean age increase of 8.49 years over the 
control population, presumably due to greater exposure through surgery or pregnancy and 
resulting risk of formation of antibodies. An elegant contrast is provided by the low incidence 
(0.05%) of alloantibodies in the healthy blood donor cohort studied by Pahuja et al [19] 
where 98.6% of the cohort was male and a large proportion were under 30 years of age.  
 
The diagnoses of GIT Bleed, Haematological Malignancy, Renal Failure and Sepsis are 
found in higher frequencies in the alloimmunised patient population, along with female sex, 
increased age and more frequent RhD negative status. From this we can hypothesise that a 
history of these diagnoses and possession of any of these demographics would be suggestive 
of a higher risk of a particular patient having already formed a red cell alloantibody, which 
would be of particular importance in the pre-operative setting. The alloimmunisation risk of 
these patients may be considerably higher than the 1.5% chance of alloimmunisation 
observed in the total patient population [7].  
 
Whilst the RhD status will only be known following serological testing, the age, sex and 
diagnosis of the patient are immediately available. These indicators allow the surgeon to 
organise the patient’s pre-admission plan to accommodate the process of finding antigen 
negative blood, and in the unfortunate event of a trauma, alerts the trauma team to the 
possibility of an alloimmunised patient. It presents an excellent opportunity for the treating 
team to provide the best level of care, and avoid the situation of the patient being in surgery 
only to have the Transfusion Laboratory phone to report that they have a red cell antibody 
and blood will take several hours to provide. First and foremost in prevention of this scenario 
is always a review of the patient’s history for any previously detected alloantibodies.  
 
5. Conclusions 
 
Several important observations can be made from the data which have potential implications 
for patient care, particularly in the situation where patients arrive at a health care institution – 
particularly one with a large patient catchment and referral area - with minimal available 
medical history. In this study, the alloimmunised patient population showed an over-
representation of GIT bleeding, haematological malignancy, renal failure and sepsis. A 
patient history of any of these diagnoses should be considered a risk factor for previous 
alloimmunisation in the presenting patient. Female patients, older patients and patients who 
are RhD Negative were also over-represented when compared to the control patient group.  
 
Whilst the patient’s RhD type is only available once the transfusion service has processed the 
patient’ sample, the patient’s sex, approximate age and immediate diagnosis are able upon 
presentation. Using the demographics and diagnoses identified in this study, patients could be 
triaged as being at low or high risk of previous alloimmunisation and treated accordingly.  
Eccles | 6 
 
 
Acknowledgements 
 
The author would like to acknowledge the work of the staff of the ACT Pathology 
Transfusion Laboratories.  
 
Conflict of interest 
 
The researcher has no conflict of interest to declare.  
 
References 
 
1. Klein, H. & Anstee, D. (2005) Blood transfusion in clinical medicine (11th Ed). 
Oxford (UK), Blackwell Publishing.  
2. Abdel Galil M., Abdel G., Abeer K., Al Ghumlas, Abdel Kareem M. A.  Transfusion 
medicine in a developing country – Alloantibodies to red blood cells in multi-
transfused patients in Saudi Arabia. Transfusion and Apheresis Science Volume 39, 
Issue 3, December 2008, Pages 199–204 
3. Koelewijn, J., Vrijkotte, T., de Haas, M., van der Schoot, C. & Bonsel, G. (2009) Risk 
factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG 
2009;116:655–664. 
4. Stiegler, G., Sperr, W., Lorber, C., Fabrizii, V., Höcker, V., Panzer, S. Red cell 
antibodies in frequently transfused patients with myelodysplastic syndrome. Ann 
Hematol (2001) 80:330–333 
5. Moise, K. Red Blood Cell Alloimmunization in Pregnancy. Seminars in 
Haematology. Division of Maternal-Fetal Medicine, University of North Carolina 
School of Medicine, Chapel Hill, NC. (2005) 
6. Verduin, E., Schonewille, H., Lindenburg, I., Lopriore, E., Oepkes, D., Doxiadis, I., 
Branda, A. Fetal induced red blood cell antibodies persist over 20 years. Journal of 
Reproductive Immunology 86 (2010) 79–111 
7. Issitt, P. & Anstee, D. (1998) Applied Blood Group Serology (4th Ed). Durham (NC), 
Mongomery Scientific Publications.  
8. Gazdag, E., Jakab, J., Zsigmond-So’os, I., Gol’acs, N., Benk˝o, S., Vagner, M,. 
Krist’ofi, Ns., Bedekovich. N. Frequency of red blood cell antibodies in adult 
patients. Oral presentations, ISH EAD 2007, Budapest, Hungary, 29 August 2 
September 2007. 
9. Schonewille, H., van der Watering, L., Brand, A. (2006). Additional red blood cell 
alloantibodies after blood transfusion in nonhaematologic alloimmunised patient 
cohort: is it time to take precautionary measures? Transfusion 2006: col 46, pp 630-
635.  
10. Redman, M., Regan, F., Contreras, M. (1996). A prospective study of the incidence of 
red cell allo-immunisation following transfusion. Vox Sanguinis Vol 71, pp 216-220.  
11. Natukunda, B., Schonewille, H., van de Watering, L., & Brand, A. (2010). Prevalence 
and specificities of red blood cell alloantibodies in transfused Ugandans with different 
diseases. Vox Sanguinis, 98(2), 167-171. Retrieved from MEDLINE with Full Text 
database. 
12. Mushkbar, M., Watkins, E. & Doughty, H. A UK single-centre survey of red cell 
antibodies in adult patients undergoing liver transplantation. Vox Sanguinis (2013) 
105, 341–345 
Eccles | 7 
 
13. Azarkeivan, A., Ahmadi, M., Gharebaghian, A., Nasizadeh, S., Zolfaghari, S., 
Maghsoodlu, M., Ayoub, M. RBC alloimmunization in chronic transfusion patients 
(thalassemics) Posters, ISH EAD 2007, Budapest, Hungary, 29 August 2 September 
2007. 
14. Poole, J. & Daniels, G. Blood Group Antibodies and Their Significance in 
Transfusion Medicine. (2007) Transfusion Medicine Reviews, vol 21, pp58-71.  
15. Yazer, M. & Triulzi, D. (2007) Detection of anti-D in D- recipients transfused with 
D+ red blood cells. Transfusion, vol 47, pp 2197-2201. 
16. Cerdas-Quesada, C. Specificity of 136 patient’s antibodies to human red blood cells in 
Dr. Max Peralta J Hospital Blood Bank 2004–February 2009. Transfusion and 
Apheresis Science 42 (2010) 105–108 
17. Moise K. Non-anti-D antibodies in red-cell alloimmunization. Eur J Obstet Gynecol 
Reprod Biol. 2000 Sep;92(1):75-81. 
18. Etzioni, D., Liu, J., Maggard, M. & Ko, C. The Aging Population and Its Impact on 
the Surgery Workforce. Annals of Surgery, Volume 238, Number 2, August 2003 
19. Pahuja S.,  Kushwaha S., Sethi N., Pujani M. & Jain M. Screening of blood donors for 
erythrocyte alloantibodies. Hematology. 2012 Sep; Vol. 17 (5), pp. 302-5. 
 
 
 Control Patients 
N=12246 
Alloimmunised 
Patients n=589 
P Value 
Sex  %  % <0.001 
Male 3868 31.55 139 23.60  
Female 8376 68.31 450 76.40  
 
ABO Blood Group  
O 5598 45.66 265 44.99 0.54 
A 4745 38.70 222 37.69  
B 1459 11.90 74 12.56  
AB 451 3.68 28 4.75  
 
RhD Status  
RhD Positive 10222 83.37 425 72.16 <0.001 
RhD Negative 2031 16.56 164 27.84  
 
Age Mean 49.95 58.44 <0.001 
Age SD 22.24 22.45  
Table 1. Demographic Results.  
Diagnosis  %  % <0.001 
Bleeding 379 3.09 14 2.38 0.322 
GIT Bleed 434 3.54 41 6.96 <0.001 
Haematological 
Malignancy 
264 2.15 34 5.77 <0.001 
Other 1668 13.60 21 3.57 <0.001 
Other Malignancy 382 3.12 30 5.09 0.059 
Pregnancy 4381 35.73 162 27.50 <0.001 
Renal Failure 164 1.34 20 3.4 <0.001 
Sepsis 136 1.11 27 4.58 <0.001 
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Surgery 3021 24.64 167 28.35 0.036 
Trauma 907 7.40 50 8.49 0.312 
Unknown 493 4.02 23 3.90 0.886 
Table 2. Diagnosis Results 
 
 
Figure 1. Male patients in age by decades 
 
 
Figure 2. Female patients in age by decades 
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